美罗华联合CHOP方案治疗侵袭性B细胞淋巴瘤疗效分析

目的探讨分析美罗华联合CHOP方案在侵袭性B细胞淋巴瘤治疗中的应用效果。方法选择2008年1月—2013年11月期间该院收治的90例侵袭性B细胞淋巴瘤患者为研究对象,随机分为观察组和对照组各45例,对照组患者给予CHOP方案治疗,观察组患者给予美罗华联合CHOP方案治疗,治疗后观察比较两组患者临床疗效和不良反应。结果观察组治疗总有效率82.22%明显高于对照组62.22%,差异有统计学意义（P〈0.05）;两组主要不良反应均为轻度或中度骨髓抑制和胃肠道反应、轻度转氨酶升高和便秘等,观察组不良反应率为31.11%高于对照组28.89%,差异无统计学意义（P〉0.05）。结论与CHOP方案单独治疗相比,美罗华联合CHOP方案在侵袭性B细胞淋巴瘤治疗中应用效果较好,且毒副作用不会增加,可作为一线治疗方案的首选。

Analysis of the Effect of Rituximab Combined with CHOP Regimen in the Treatment of Aggressive B-cell Lymphoma

Objective To summarize and analyze the application effect of rituximab combined with CHOP regimen in the treatment of aggressive B-cell lymphoma. Methods 90 patients with aggressive B-cell lymphoma admitted in our hospital from January,2008 to November, 2013 were divided into the control group（45 cases）, treated by CHOP regimen and the observation group（45cases）, treated by rituximab combined with CHOP regimen. The clinical efficacy and adverse reactions of two groups were compared. Results After treatment, the total efficiency of the observation group was 82.22%, significantly higher than that（62.22%） of the control group, the difference was statistically significant（P〈0.05）. Major adverse reactions of two groups were mild or moderate myelosuppression and gastrointestinal reactions, mild transaminase elevation and constipation. The incidence of adverse reactions of the observation group was 31.11%, which was higher than that（28.89%） of the control group, but with no statistically significant difference（P〉0.05）. Conclusion Compared with the CHOP regimen alone, the rituximab combined with CHOP regimen in the treatment of aggressive B-cell lymphoma has better efficacy without increasing the side effects, which can be used as the first-line treatment regimen.